Daniel A. Estevez-Garcia

Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis.

Journal: International journal of molecular sciences

Published: April 15, 2026

CefaleApp: A Mobile Application for Migraine Diagnosis in Primary Health Care

Journal: Revista de neurologia

Published: September 11, 2025

Hyperbaric oxygen therapy as a therapeutic option for post-COVID syndrome fatigue.

Journal: Neurologia

Published: July 02, 2025

Effectiveness of Risdiplam Treatment in Adult Patients With Spinal Muscular Atrophy Type IIb-III.

Journal: Revista de neurologia

Published: June 30, 2025

[Translated article] Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years.

Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

Published: May 01, 2025

Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years.

Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

Published: May 01, 2025

Organizing Pneumonia and Immunomediated Colitis Associated with Ocrelizumab Treatment.

Journal: Annals of Indian Academy of Neurology

Published: July 27, 2024

Reduction of plasma CGRP levels in migraine patients treated with erenumab or galcanezumab.

Journal: Revista de neurologia

Published: May 14, 2024

Alemtuzumab and autoimmune polyglandular syndrome with type 1 diabetes mellitus.

Journal: Neurologia

Published: February 22, 2024

Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.

Journal: Neurology and therapy

Published: May 29, 2023

Hyperbaric oxygen therapy in long-COVID-19 disease

Journal: Medicina clinica

Published: May 28, 2023

Dopa-responsive dystonia and young-onset parkinsonism in a patient with heterozygous mutation in SPR and PRKN treated with pallidal stimulation.

Journal: Neurologia

Published: April 12, 2023

Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis.

Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis.

CefaleApp: A Mobile Application for Migraine Diagnosis in Primary Health Care

CefaleApp: A Mobile Application for Migraine Diagnosis in Primary Health Care

Hyperbaric oxygen therapy as a therapeutic option for post-COVID syndrome fatigue.

Hyperbaric oxygen therapy as a therapeutic option for post-COVID syndrome fatigue.

Effectiveness of Risdiplam Treatment in Adult Patients With Spinal Muscular Atrophy Type IIb-III.

Effectiveness of Risdiplam Treatment in Adult Patients With Spinal Muscular Atrophy Type IIb-III.

[Translated article] Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years.

[Translated article] Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years.

Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years.

Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years.

Organizing Pneumonia and Immunomediated Colitis Associated with Ocrelizumab Treatment.

Organizing Pneumonia and Immunomediated Colitis Associated with Ocrelizumab Treatment.

Reduction of plasma CGRP levels in migraine patients treated with erenumab or galcanezumab.

Reduction of plasma CGRP levels in migraine patients treated with erenumab or galcanezumab.

Alemtuzumab and autoimmune polyglandular syndrome with type 1 diabetes mellitus.

Alemtuzumab and autoimmune polyglandular syndrome with type 1 diabetes mellitus.

Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.

Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.

Hyperbaric oxygen therapy in long-COVID-19 disease

Hyperbaric oxygen therapy in long-COVID-19 disease

Dopa-responsive dystonia and young-onset parkinsonism in a patient with heterozygous mutation in SPR and PRKN treated with pallidal stimulation.

Dopa-responsive dystonia and young-onset parkinsonism in a patient with heterozygous mutation in SPR and PRKN treated with pallidal stimulation.

[Translated article] Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years.

[Translated article] Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years.

Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years.

Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years.